Ryan Deschner
Stock Analyst at Raymond James
(2.96)
# 1,424
Out of 4,786 analysts
9
Total ratings
77.78%
Success rate
20.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INZY Inozyme Pharma | Maintains: Outperform | $24 → $12 | $0.91 | +1,218.68% | 1 | Mar 12, 2025 | |
| TRVI Trevi Therapeutics | Upgrades: Strong Buy | $9 → $29 | $6.29 | +361.05% | 2 | Mar 10, 2025 | |
| ARDX Ardelyx | Reiterates: Strong Buy | $15 → $13 | $4.91 | +164.77% | 1 | Feb 21, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $12.58 | +122.58% | 3 | Jan 14, 2025 | |
| LQDA Liquidia | Upgrades: Strong Buy | $27 | $14.75 | +83.05% | 2 | Aug 19, 2024 |
Inozyme Pharma
Mar 12, 2025
Maintains: Outperform
Price Target: $24 → $12
Current: $0.91
Upside: +1,218.68%
Trevi Therapeutics
Mar 10, 2025
Upgrades: Strong Buy
Price Target: $9 → $29
Current: $6.29
Upside: +361.05%
Ardelyx
Feb 21, 2025
Reiterates: Strong Buy
Price Target: $15 → $13
Current: $4.91
Upside: +164.77%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $12.58
Upside: +122.58%
Liquidia
Aug 19, 2024
Upgrades: Strong Buy
Price Target: $27
Current: $14.75
Upside: +83.05%